# rhTSH for Radioactive Iodine Remnant Ablation in Participants With Differentiated Thyroid Cancer (DTC)

Source: https://onco.cc/trials/nct04964284/  
OnCo record `nct04964284` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Thyrotropin alfa in Thyroid cancer, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, completed.

## Summary

rhTSH for Radioactive Iodine Remnant Ablation in Participants With Differentiated Thyroid Cancer (DTC) is a phase 3 interventional study registered as NCT04964284 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 390 participants recorded, started 2021-10-06 and reaching its primary completion in 2026-01-31. Interventions recorded: rhTSH, Radioiodine (131I). Conditions recorded: Differentiated Thyroid Cancer.

Linked to the drug Thyrotropin alfa because the registry names it among its interventions and Thyroid cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04964284
- Phase: 3
- Setting: A Phase 3, Randomized, Open-Label, Multicenter, Parallel-Group Study to Evaluate the Efficacy and Safety of Recombinant Human Thyrotropin (rhTSH) for Radioactive Iodine (RAI) Remnant Ablation in Postoperative Participants With Differentiated Thyroid Cancer (DTC)
- Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Enrolled: 390

## Sources

- ClinicalTrials.gov NCT04964284: https://clinicaltrials.gov/study/NCT04964284

## Connected records

- cancers: [Thyroid cancer](https://onco.cc/cancers/thyroid/)
- drugs: [Thyrotropin alfa](https://onco.cc/drugs/thyrotropin-alfa/)
- companies: [Suzhou Zelgen Biopharmaceuticals](https://onco.cc/companies/zelgen/)

---
JSON: https://onco.cc/api/v1/entities/nct04964284.json